Skip to main content

Table 1 Characteristics of randomized controlled trials included in this meta-analysis

From: Efficacy and safety of cinacalcet compared with other treatments for secondary hyperparathyroidism in patients with chronic kidney disease or end-stage renal disease: a meta-analysis

Authors/year of publication Country Mean age (years) Stage of CKD Intervention Duration of the trial Outcomes assessed
Cinacalcet Control
Goodman/2000 [12] USA Cinacalcet 48.6 (12.4)
Control 54.7 (16.8)
HD R-568, 100 mg/d,
N = 16
Placebo, N = 5 24 days All-cause mortality, cardiovascular mortality, nausea, and hypocalcemia.
Goodman/2002 [13] USA NA HD AMG 073, 10–50 mg/d,
N = 23
Placebo, N = 7 15 days All-cause mortality, cardiovascular mortality, nausea, and hypocalcemia.
Lindberg/2003 [14] USA Cinacalcet 52.7 (16.4)
Control 48.8 (15.6)
HD AMG 073, 10–50 mg/d,
N = 39
Placebo, N = 39 18 weeks Serum PTH, all-cause mortality, cardiovascular mortality, nausea, and hypocalcemia.
Quarles/2003 [15] USA Cinacalcet 49.6 (8.5)
Control 47.9 (14.2)
HD AMG 073, 25–100 mg/d,
N = 36
Placebo, N = 35 18 weeks Serum PTH, calcium, phosphate, and calcium phosphorus product.
Block/2004 [9] USA Cinacalcet 54 (14)
Control 55 (15)
HD Cinacalcet, 30–180 mg/d,
N = 371
Placebo, N = 370 26 weeks Serum PTH, phosphate, calcium phosphorus product, all-cause mortality, nausea, vomiting, and hypocalcemia.
Charytan/2005 [16] USA Cinacalcet 60.6 (15.6)
Control 61.9 (15.1)
CKD Cinacalcet, 30–180 mg/d,
N = 27
Placebo, N = 27 18 weeks All-cause mortality, cardiovascular mortality, nausea, and hypocalcemia.
Lindberg/2005 [17] USA Cinacalcet 51.8 (14)
Control 53.5 (13.9)
HD
PD
Cinacalcet, 30–180 mg/d,
N = 294
Placebo, N = 101 26 weeks Serum PTH, calcium, phosphate, calcium phosphorus product, all-cause mortality, nausea, and vomiting.
Akiba/2008 [18] Japan Cinacalcet 56.7 (9.2)
Control 51.8 (7.5)
HD Cinacalcet, 12.5–50 mg/d,
N = 91
Placebo, N = 30 5 weeks All-cause mortality, cardiovascular mortality, nausea, vomiting, and hypocalcemia.
Fishbane/2008 [19] USA Cinacalcet 57.7 (14.9)
Control 59 (12.4)
HD Cinacalcet,
30–180 mg/d plus paricalcitol 2 g or doxercalciferol 1 g,
N = 87
Paricalcitol 2 g or doxercalciferol 1 g,
N = 86
27 weeks All-cause mortality, nausea, vomiting, hypercalcemia, and hypocalcemia.
Fukagawa/2008 [20] Japan Cinacalcet 54.7 (11)
Control 55.7 (11.7)
HD Cinacalcet, 30–180 mg/d,
N = 72
Placebo, N = 71 14 weeks Serum calcium, phosphate, calcium phosphorus product, all-cause mortality, cardiovascular mortality, nausea, vomiting, and hypocalcemia.
Messa/2008 [21] Italy Cinacalcet 58.5 (14.5)
Control 58.3 (14.5)
HD Cinacalcet, 30–180 mg/d,
N = 368
Conventional Care,
N = 184
23 weeks Serum PTH, calcium, phosphate, calcium phosphorus product, all-cause mortality, cardiovascular mortality, nausea, vomiting, and hypocalcemia.
Chonchol/2009 [22] USA Cinacalcet 64.7 (13.3)
Control 66.2 (12.2)
CKD Cinacalcet, 30–180 mg/d,
N = 302
Placebo,
N = 102
32 weeks Serum calcium, phosphate, calcium phosphorus product, all-cause mortality, cardiovascular mortality, nausea, vomiting, and hypocalcemia.
EI-Shafey/2011 [23] Egypt Cinacalcet 51.5 (12.7)
Control 51.8 (15.0)
HD Cinacalcet, 30–180 mg/d,
N = 55
conventional therapy
(intravenous alfacalcidol thrice weekly at the end of their dialysis session and phosphate binders), N = 27
36 weeks Serum PTH, calcium, phosphate, calcium phosphorus product, all-cause mortality, nausea, vomiting, and hypocalcemia.
Raggi/2011 [24] USA Cinacalcet 61.2 (12.6)
Control 61.8 (12.8)
HD Cinacalcet, 30–180 mg/d
plus low-dose vitamin D,
N = 180
Same dose of vitamin D prescribed N = 180 52 weeks All-cause mortality, hypercalcemia, and hypocalcemia.
EVOLVE/2012 [25] USA Cinacalcet 55.0 (35–74)
Control 54.0 (35–73)
HD Cinacalcet, 30–180 mg/d,
N = 1948
Placebo, N = 1935 20 weeks All-cause mortality, cardiovascular mortality, nausea, vomiting, hypercalcemia, and hypocalcemia.
Ketteler/2012 [26] Germany Cinacalcet 59.9 (12.0)
Control 61.2 (12.7)
HD Cinacalcet (dose unclear) plus low-dose vitamin D
N = 134
Paricalcitol 0.07 μg/kg IV
or iPTH/60 PO N = 134
28 weeks All-cause mortality, cardiovascular mortality, nausea, vomiting, hypercalcemia, and hypocalcemia.
Kim/2013 [27] Korea Cinacalcet 48.8 (11.5)
Control 47.2 (8.4)
PD Cinacalcet, 25–50 mg/d plus low-dose vitamin D,
N = 33
N = 33
Same dose of vitamin D
prescribed N = 33
20 weeks All-cause mortality and cardiovascular mortality.
Urena-Torres/2013 [28] France Cinacalcet 57.9 (13.6)
Control 57.0 (14.6)
HD Cinacalcet, 25–50 mg/d plus low-dose vitamin D, N = 154 Same dose of vitamin D
prescribed N = 155
52 weeks All-cause mortality, nausea, vomiting, hypercalcemia, and hypocalcemia.
Bell/2015 [29] USA Cinacalcet 52.4 (13.7)
Control 50.7 (13.6)
HD Cinacalcet, 5–10 mg/d,
N = 40
Placebo, N = 38 4 weeks All-cause mortality, nausea, vomiting, and hypercalcemia.
Wetmore/2015[30] USA Cinacalcet 53 (21–81)
Control 55 (22–86)
HD Cinacalcet, 30–180 mg/d,
N = 155
vitamin D (dose unclear),
N = 157
52 weeks Serum PTH, calcium, phosphate, all-cause mortality, hypercalcemia, and hypocalcemia.
Mei/2016[31] China Cinacalcet 50.02 (11.17)
Control 50.12 (11.34)
HD Cinacalcet, 25–100 mg/d,
N = 118
Placebo, N = 114 16 weeks Serum PTH, calcium, phosphate, calcium phosphorus product, nausea, vomiting, and hypocalcemia.
  1. CKD Chronic kidney disease, HD hemodialysis, NA not available, PTH parathyroid hormone,aPD peritoneal dialysis
\